4D pharma plc

DB:4DY Stock Report

Market Cap: €34.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

4D pharma Management

Management criteria checks 3/4

Key information

Duncan Peyton

Chief executive officer

US$343.9k

Total compensation

CEO salary percentage98.8%
CEO tenure8.6yrs
CEO ownership5.6%
Management average tenure8.3yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Duncan Peyton's remuneration changed compared to 4D pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2021US$344kUS$340k

-US$32m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$41m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$139kUS$137k

-US$30m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$135kUS$132k

-US$30m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$130kUS$127k

-US$30m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$25m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$137kUS$137k

-US$28m

Sep 30 2017n/an/a

-US$25m

Jun 30 2017n/an/a

-US$22m

Mar 31 2017n/an/a

-US$17m

Dec 31 2016US$125kUS$125k

-US$12m

Sep 30 2016n/an/a

-US$12m

Jun 30 2016n/an/a

-US$11m

Mar 31 2016n/an/a

-US$11m

Dec 31 2015US$149kUS$149k

-US$11m

Compensation vs Market: Duncan's total compensation ($USD343.93K) is about average for companies of similar size in the German market ($USD418.19K).

Compensation vs Earnings: Duncan's compensation has increased whilst the company is unprofitable.

CEO

Duncan Peyton (52 yo)

8.6yrs

Tenure

US$343,931

Compensation

Mr. Duncan Joseph Peyton is a Co-founder of Retroscreen Virology Group plc. Mr. Peyton serves as Chief Executive Officer at 4D pharma plc. since February 2014.Mr. Peyton served at Aquarius Equity Partners...

Leadership Team

NamePositionTenureCompensationOwnership
Duncan Peyton
CEO & Executive Director8.6yrsUS$343.93k5.55%
€ 1.9m
Alexander Stevenson
Chief Scientific Officer & Executive Director8.3yrsUS$295.18k5.4%
€ 1.9m
John Doyle
Chief Financial Officerless than a yearno datano data
Fay Weston
Head of Investor Relationsno datano datano data
Adrian Murray
General Counsel (Interim)no datano datano data
Glenn Dourado
Executive Vice President of Corporate Developmentno datano datano data
Lucy Christie
Vice President of Human Resourcesno datano datano data
Christophe Carite
Senior Vice President of CMC & Process Developmentno datano datano data
Imke Mulder
Executive Vice President of Researchno datano datano data

8.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 4DY's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Duncan Peyton
CEO & Executive Director8.7yrsUS$343.93k5.55%
€ 1.9m
Alexander Stevenson
Chief Scientific Officer & Executive Director8.7yrsUS$295.18k5.4%
€ 1.9m
Paul Maier
Independent Non-Executive Director1.5yrsUS$90.72kno data
Edgardo Baracchini
Independent Non-Executive Director3.7yrsUS$93.43kno data
Katrin Rupalla
Independent Non-Executive Director2yrsUS$93.43kno data
Alexander Macrae
Independent Non-Executive Director3.1yrsUS$100.20kno data
Axel Glasmacher
Independent Non-Executive Chairperson3.7yrsUS$139.47k0.017%
€ 5.7k

3.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 4DY's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/09/21 12:00
End of Day Share Price 2022/06/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

4D pharma plc is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
Keay NakaeChardan Capital Markets, LLC
Gbolahan Amusa BenzChardan Capital Markets, LLC